Sector
PharmaceuticalsOpen
₹148.1Prev. Close
₹147.9Turnover(Lac.)
₹3,205.97Day's High
₹152.85Day's Low
₹145.2552 Week's High
₹166.752 Week's Low
₹87.5Book Value
₹50.65Face Value
₹10Mkt Cap (₹ Cr.)
20,074.48P/E
50.24EPS
2.93Divi. Yield
0.0710 May 2024
12:00 AM
Dividend
Dividend Amount: 0.11
Record Date: 12 Jul, 2024
30 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
27 Jul 2023
12:00 AM
Rights
25 May 2023
12:00 AM
AGM
Announcement Date: 25 May, 2023
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 1,322.95 | 1,193.32 | 1,185.91 | 994.7 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,389.12 | 4,068.47 | 3,937.21 | 3,105.92 |
Net Worth | 6,712.07 | 5,261.79 | 5,123.12 | 4,100.62 |
Minority Interest |
No Record found
No Record found
No Record found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|
Gross Sales | 8,171.16 | 7,081.55 | 6,559.1 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 8,171.16 | 7,081.55 | 6,559.1 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 234.88 | 279.44 | 334.83 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Nandini Piramal
Executive Director & CEO
PETER D DEYOUNG
Non Executive Director
Neeraj Bharadwaj
Independent Director
Jairaj Purandare
Independent Director
S Rama Dorai
Independent Director
Peter Stevenson
Independent Director
Sridhar Gorthi
Independent Director
Vibha Paul Rishi
Executive Director & CFO
Vivek Valsaraj
Company Sec. & Compli. Officer
Tanya DCosta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Piramal Pharma Ltd
Summary
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan(now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paid-up equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ bio-therapeutics and vaccine segments. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, i-Pill and Polycrol.Apart from this, the Company offers differentiated capabilities in niches areas suc
Read More
What is the Piramal Pharma Ltd share price today?
The Piramal Pharma Ltd shares price on N/A is Rs.₹151.6 today.
What is the Market Cap of Piramal Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Piramal Pharma Ltd is ₹20098.34 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Piramal Pharma Ltd?
The PE and PB ratios of Piramal Pharma Ltd is 50.24 and 2.91 as of 22 Jul ‘24
What is the 52 Week High and Low of Piramal Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Piramal Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Piramal Pharma Ltd is ₹87.55 and ₹166.6 as of 22 Jul ‘24
What is the CAGR of Piramal Pharma Ltd?
Piramal Pharma Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 48.85%, 6 Month at 2.51%, 3 Month at 5.56% and 1 Month at -4.51%.
What is the shareholding pattern of Piramal Pharma Ltd?
The shareholding pattern of Piramal Pharma Ltd is as follows:
Promoters - 34.95 %
Institutions - 44.37 %
Public - 20.21 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
